CA-19-9 ELISA kit

CA-19-9 (Gastrointestinal Cancer Antigen) ELISA Kit which is an enzyme-linked immunosorbent assay for the quantitative measurement of Gastrointensinal Cancer Antigen (CA-19-9) concentration in human serum. An elevated serum CA19-9 suggests the need for further clinical management. The CA-19-9 ELISA kit, like many ELISA KITS, is for diagnostic laboratory use only.

As in other Cancer ELISA Kits, the CA-19-9 ELISA kit is a solid phase two-site immunoassay. The CA-19-9 ELISA kit is intended to be used as a monitoring and screening test, and is useful for patients in clinical remission, as post-operative serum CA-19-9 values which fail to return to normal, strongly suggest the presence of residual tumor. Tumor recurrence is often accompanied by a rise of serum levels before progressive disease is clinically evident. The sensitivity of the CA-19-9 ELISA kit is 5 U/ml and the specificity is 97%.

Notable features of Cancer ELISA Kits:

▪ User-friendly directions and explanation of test procedures
▪ Simple and safe reagent preparation
▪ Clear instructions on specimen collection
▪ Comprehensive package of required materials
▪ Explicit quality control and storage guidelines
▪ Reliable and easy-to-read test results

Product inserts for most Cancer ELISA kits follow a similar method. See the CA-19-9 ELISA Kit product insert for details on preparation, procedures, quality control, and test result interpretation.

Gentaur also provides other ELISA Kits. 

For more information download PDF file 

Eine Krankenschwester von einem Krankenhaus, das Frankreichs einzigen bestätigten Fall des SARS ähnlichen Coronavirus der bereits 18 Menschen getötet hat gab selbst zu möglicherweise selber infiziert zu sein, sagte die Französiche Gesundheitsbehörde am Freitag.

Die Weltgesundheitsorganisation (WHO) erhöhte die Zahl der bestätigten Fälle Weltweit zu 33 nachdem Saudi Arabien sagte, dass zwei Menschen die ins Krankenhaus eingeliefert wurden dort im April durch Laboranalyse bestimmt worden waren mit dem Virus infiziert zu sein…

Lesen Sie die ganze Geschichte HIER.

Nicht zuletzt ist die Entstehung eines neuartigen Coronavirus (nCoV)eine wietere Bedrohung von neuen Viren der wir bevorstehen. Da viele von diesen Viren mit dem Menschen von wilden Tieren überqueren, weil Menschen immer tiefer und tiefer in den natürlichen Lebensraum von vielen Kreaturen reingraben. Und wir leben in einer Zeit, wo jeder neue Virus weniger als 24 Stunden von überall auf der Erde entfernt ist.

GENTAUR biete Ihnen eine Vielzahl von RT-PCR Assays, ELISA Kits, cDNAs und anderen molekularen Reagenzien, die uns helfen eine schnelle Antwort auf alle diese kommenden Bedrohungen zu finden.

*ELISA Kits

DEIA1035SARS Coronavirus IgG ELISA Kit - 1912 EUR

DEIA1036SARS Coronavirus IgM ELISA Kit - 1912 EUR

DEIA1035/DEIA1036: Dieses Kit verwendet eine feste Phase, indirekte ELISA assay zum Nachweis von IgG/IgM antikörper gegen SARS Coronavirus in zweistufigen Inkubations Verfahren. Mikrotiter Streifen warden vorher mit Coronavirus Antigenen gereinigt.

*Recombinante virale Antigene

- SARS-Assoziierte Coronavirus E recombinantes Antigen a.a. 1-76., #00191-v – 830 euro

- SARS-Assoziierte Coronavirus Nucleocapsid recombinanest Antigen N a.a. 1-49., #00192-v – 830 euro

- SARS-Assoziierte Coronavirus Nucleocapsid recombinantes Antigen C a.a. 340-390., #00193-v – 830 euro

- SARS-Assoziierte Coronavirus M recombinantes Antigen a.a. 182-216., #00194-v– 830 euro

-  SARS-Associated Coronavirus Spike mosaic recombinantes Antigen S(N) a.a. 12-53/90-115/171-203., #00195-v – 830 euro

- SARS-Associated Coronavirus Spike mosaic recombinantes Antigen S(M) a.a. 408-470/540-573., #00196-v – 830 euro

- SARS-Associated Coronavirus Spike mosaic recombinantes Antigen S© a.a. 1051-1076/1121-1154/1162-1190., #00197-v – 830 euro

Antikörper:

- Maus Monoklonal Anti-Mensch schweree akutes respiratorisches Syndrom (SARS-E2) Spezies Reactivität: menschlicher Coronavirus, #MA-20018,- 459 euro

- Maus Monoklonal Anti-Mensch schweres akutes respiratorosches Syndrom (SARS)-M Species Reactivity: menschlicher Coronavirus, # MA-20018, - 459 euro

- Anti-SARS Spitzenprotein IgG Spezies Reactivität: SARS, #AB-15710, - 433 euro

- Maus Anti-SARS Nucleocapsidprotein IgG Species Reactivität: MAUS, #AB-17810, - 498 euro

- Maus Anti-SARS Spike IgG Spezies Reactivität: MAUS, #AB-17910, - 498 euro

- Anti-SARS Nucleocapsidprotein IgG Spezies Reactivität: SARS, #AB-18010, - 498 euro

Recombinantes SARS-ACSM Antigen kann in ELISA und Western Blots verwendet werden, hervorragend für den Nachweis von SARS mit minimalen Spezifität Problemen!

SARS-ACSMS(M) (Reste 408-470, 540-573) SARS-Assoziiertes Coronavirus Spike Mosaic S(M)recombinant, E. Coli, #PR-1106, - 194 euro

SARS-ACSMS(C) (Reste 1051-1076, 1121-1154, 1162-1190) SARS-Assoziiertes Coronavirus Spike Mosaic S(C)recombinant, E. Coli, #PR-1105, -194 euro

SARS-ACN/3 (Reste 1-49, 192-220) SARS-Assoziiertes Coronavirus Nucleocapsid recombinant, E. Coli, #PR-1104 - 194 euro

SARS-ACN/2 (Reste 1-49) SARS-Assoziiertes Coronavirus Nucleocapsid recombinant, E. Coli, #PR-1103, - 194 euro

SARS-ACN/1 (Reste 340-390) SARS-Assoziiertes Coronavirus Nucleocapsid recombinant, E. Coli,PR-1102, - 194 euro

SARS-ACM (Reste 182-216) SARS-Assoziiertes Coronavirus Matrix rekombinant, E. Coli PR-1101,- 194 euro

SARS-ACE (Reste 1-76) SARS-Assoziiertes Coronavirus Umschlags rekombinant, E. Coli,PR-1100, - 194 euro

*Menschliches SARS cDNA Klon

Menschliches SARS cDNA klon, 10 g, Orf Größe: 1545, Vektor: pcDNA4/TO/myc-His A, # DC00346–  181 euro

PRODUCT DESCRIPTION:
NATtrol™ MRSA.SA Panel (NATMRSA.SAP-C) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATMRSA.SAP-C contains 5 x 0.5 mL vials of S. aureus or S. epidermidis NATtrol™ as listed in Table 1. These panels are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ MRSA.SA Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of S. aureus DNA. NATMRSA.SAP-C can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATMRSA.SAP-C contains intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on the bacterial stock used to formulate panel members. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

Catalog #: NATMRSA.SAP-C

For more information download PDF file

PRODUCT DESCRIPTION:
NATtrol™ Influenza External Run Controls (NATFLUA.B-6MC, NATFLUAH1N1-6MC and NATCXVA9-6MC) are formulated with purified, intact virus particles that have been chemically modified to render them non-infectious and refrigerator stable*. Each control contains 6 x 0.5 mL vials of NATtrol™ Influenza A.B or Influenza A H1N1 (2009) or Coxsackie virus A9 NATtrol™.  These controls are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ Influenza External Run Controls are designed to evaluate the performance of nucleic acid tests for determination of the presence of respiratory virus nucleic acids. NATFLUA.B-6MC, NATFLUAH1N1-6MC and NATCXVA9-6MC can also be used for quality control of clinical assays and training of laboratory personnel.
- NATFLUA.B-6MC, NATFLUAH1N1-6MC and NATCXVA9-6MC contain intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on each control. The inactivation was verified by the absence of virus growth in a validated tissue culture based infectivity assay.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab,HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

Catalog #:NATFLUA.B-6MC
Catalog #:NATFLUAH1N1-6MC
Catalog #:NATCXVA9-6MC

For more information download PDF file

It is possible soon to be established treatment for cocaine dependence. Researchers at Cornell University, have developed a vaccine which prevents cocaine enters the brain and cause euphoria, thus helps the treatment of addiction. The vaccine provides effective treatment, even if the intake of cocaine to be repeated occasionally.

Cornell researchers have successfully implemented vaccine in animal models and are very close to clinical trials in humans. According to Dr. Ronald Crystal, research should begin by the end of the year.

Cocaine blocks the reverse capture of dopamine in the synaptic cleft, which connect the nerve cells to each other. Dopamine is a neurotransmitter that creates a feeling of pleasure and enjoyment. Increasing levels of dopamine in the synaptic cleft is responsible for the euphoria that occurs after taking cocaine.

It prevents the excessive accumulation of domapin in synapses. It contains inactivated viruses on which is "attached" substance chemically resembling cocaine. This allows the immune system to recognize cocaine and his relatives compounds that neutralize it.

For the occurrence of cocaine euphoria necessary cocaine molecules to occupy at least 47% of the dopamine in nerve cells. Of the vaccine in human primates show that cocaine molecules able to occupy less than 20% of dopamine transporters.

Researchers expect the vaccine to be effective in humans, but still can not say how often you should be administered to maintain its effect. For now, just be sure that it will be necessary to apply booster doses.
 
According to official data, in the U.S. there are 1.9 million people using cocaine, 1.4 million of whom are dependent on it. Every year there are over 2 million visits to emergency departments due to drug abuse. Almost 500,000 of them are making the cocaine. Anti-cocaine vaccine has the potential to drastically reduce this number.

PRODUCT DESCRIPTION:
NATtrol™ CT.NG Panel (NATCT.NGP-C) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATCT.NGP-C panel contains 17 x 1.2 mL vials each containing the bacterial NATtrol™ targets listed in the Expected Results. These controls are  supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ CT.NG Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence bacterial DNA. NATCT.NGP-C can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATCT.NGP-C contains intact organisms and should be run in a manner identical to that used
for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on each member in the panel. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

Catalog #: NATCT.NGP-C

For more information download PDF file

PRODUCT DESCRIPTION:
NATtrol™ CT.NG External Run Controls (NATCT (434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC) are formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. Each control pack contains 6 x 1.0 mL vials of C.trachomatis NATtrolTM, N.gonorrhoeae NATtrolTM or CT.NG Negative NATtrolTM. These controls are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ CT.NG External Run Controls are full process controls designed to evaluate the performance of nucleic acid tests for determination of the presence of CT.NG DNA. NATCT(434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC can also be used for quality control of clinical assays and training of laboratory personnel.
- NATCT(434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC contain intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on each control. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

Catalog #:NATNG-6MC
Catalog #:NATCT(434)-6MC
Catalog #:NATCT.NGNEG-6MC

For more information download PDF file

PRODUCT DESCRIPTION:
NATtrol™ BC.GP Panel (NATBC.GP-NNS) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATBC.GP-NNS contains 11 x 0.75 mL vials of bacterial NATtrol™ targets listed in Table 1. These panels are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

INTENDED USE:
- NATtrol™ BC.GP Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of bacterial nucleic acids. NATBC.GP-NNS can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATBC.GP-NNS contains intact organisms and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:
- NATtrol™ inactivation was carried out on the bacterial stock used to formulate panel members. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
- The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

PRECAUTIONS:
- Although NATBC.GP-NNS contains inactivated organisms, it should be handled as if potentially infectious.
- Use Universal Precautions when handling this product.
- To avoid cross-contamination, use separate pipette tips for all reagents.

Catalog #: NATBC.GP-NNS 

For more information donwload PDF file

A MUST FOR:

• - Mouse-On-Mouse
• - Human and Animal IHC
• - Immunofluorescence
• - in-situ Hybridization

Background Buster is highly effective for quenching background fluorescence and is easy to use: 

For Fluorescence:

• Apply Background Buster for 15 minutes prior to application of the first antibody (unlabeled or fluorescence-labeled antibody).
• Rinse with PBS for 1 minute.
• Apply unlabeled antibody for indirect method or fluorescence labeled antibody for direct method and continue with usual protocol.

Background Buster can be used for IHC:

Background or non-specific staining is often observed in a variety of immunoassays, in immunohistochemistry and other immunoassay types such as immunofluorescence, ELISA and flow cytometric assays, background staining can be prevented by the use of INNOVEX Recombinant Protein Technology,Background Buster.

Background Buster is also applicable to eliminating non-specific binding in immunofluorescence, ELISA and flow cytometric assays.

ADVANCED & UNIQUE FEATURES:

• Allows staining of identical species antibodies and tissues (e.g., mouse antibody on mouse tissue, rat-on-rat, rabbit-on-rabbit, etc.).
• Short 10 minute incubation step prior to applying primary antibody or in-situ probe at room temperature
• Delivers complete eradication of general background staining
• Replaces the use of normal serum, powdered milk, casein, and other blocking agents and renders complete success
• Excellent for both frozen and paraffin sections
• Excellent for in situ application
• A must for animal tissue staining

Download datasheet PDF file

In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options. Pancreatic cancer kills nearly 38,000 Americans annually, making it a leading cause of cancer death. The life expectancy for most people diagnosed with it is less than a year.

Now new research reveals a possible chink in the armor of this recalcitrant disease. Many cancers, including pancreatic, lung, and colon cancer, feature a mutated protein known as Ras that plays a central role in a complex molecular chain of events that drives cancer cell growth and proliferation. It is well known that Ras cancer cells have special nutrient requirements to grow and survive. But how Ras cells cope to actually meet their extraordinary nutrient requirements has been poorly understood—until now. In the study, led by Cosimo Commisso, a postdoctoral fellow in the Department of Biochemistry and Molecular Pharmacology at NYU School of Medicine, show for the first time how Ras cancer cells exploit a process called macropinocytosis to swallow up the protein albumin, which cells then harvest for amino acids essential for growth.

"A big mystery is how certain tumors meet their excessive nutrient demands ," says Dr. Commisso, whose work is funded in part by the Pancreatic Cancer Action Network. "We believe they accomplish this by macropinocytosis."

The findings suggest that Ras cancer cells are particularly dependent on macropinocytosis for growth and survival. When the researchers used a chemical to block the uptake of albumin via macropinocytosis in mice with pancreatic tumors, the tumors stopped growing and in some cases even shrank. Moreover, pancreatic cancer cells in mice featured more macropinosomes—the vesicles that transport nutrients deep into a cell—than normal mouse cells.

The discovery of a "protein eating" mechanism unique to some cancer cells sets the stage for drugs that could block the engulfing process without causing collateral damage to healthy cells and suggests new ways to ferry chemotherapeutic cargo into the heart of cancer cells.

"This work offers up a completely different way to target cancer metabolism," says lead principal investigator of the study Dafna Bar-Sagi, PhD, senior vice president and vice dean for Science, chief scientific officer and professor, Department of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, who first identified macropinocytosis in Ras-transformed cancer cells. "It's exciting to think that we can cause the demise of some cancer cells simply by blocking this nutrient delivery process."

Crucial to the team's findings is the work of Matthew G. Vander Heiden, assistant professor of biology at the David H. Koch Institute for Integrative Cancer Research at MIT and Christian Metallo, assistant professor of bioengineering at the University of California at San Diego, who characterized how Ras cells derive energy from the constituent amino acids released after protein engulfment.

Other key contributors include Craig B. Thompson, president and CEO of the Memorial Sloan-Kettering Cancer Center and Joshua D. Rabinowitz, professor of chemistry at the Lewis Sigler Institute for Integrative Genomics at Princeton University.